drugset / Trial / NCT03063203
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Phase 2
Terminated
17 enrolled
Washington University School of Medicine
Janssen Pharmaceuticals · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.
Timeline
- Start
- 2017-07-14
- Primary completion
- 2021-02-13
- Completion
- 2022-03-16
Outcome
Outcome not reported
Stopped: “Futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |